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Introduction
Behcet's disease is a chronic, systemic, inflammatory disease of unknown origin. Its major clinical manifestations are oral ulcers, genital ulcers, uveitis, and skin lesions, and its other manifestations are multiple arthritis, gastrointestinal lesions, central nervous system involvement, and vascular lesions.
Small or large vessel vasculitis in Behcet's disease leads to vessel occlusion or aneurysm formation (1) , but arterial involvement occurs infrequently and presents as aortitis or a peripheral arterial aneurysm with arterial thrombosis. The pulmonary artery is the second most common site of arterial involvement in Behcet's disease (2) , and pulmonary artery aneurysms can cause massive hemoptysis by rupture in bronchi. Venous thrombosis is also present in one-fourth of Behcet's disease patients, and deep venous thrombosis of the lower limb is the most frequent venous manifestation. Few cases of Behcet's disease in a female patient combined with a pulmonary artery aneurysm and deep venous thrombosis have been reported (3) . In this article, we describe a case of Behcet's disease that was complicated by a pulmonary artery aneurysm and deep venous thrombosis, separately occurred with 5 years interval.
Case Report
A 41 year-old woman was admitted with a 2-month history of hemoptysis and sustained cough. Initially, amount of hemoptysis was small manifesting as blood-tinged sputum. CT angiovenography revealed a thrombus in the left superficial femoral vein and popliteal vein (Figure 4 ). IVC filter (OPTEASE, Cordis, USA) insertion was performed for endovascular management. After filter insertion, loading dose of urokinase 100,000 IU and heparin 5,000 IU was infused through the distal portion of the left popliteal vein. After infusing regional thrombolytics, the remnant thrombus was manually removed. Two weeks later, IVC filter was removed. Leg pain and swelling improved after flow-directed regional thrombolytic therapy, and there were no evidence of a secondary pulmonary embolism or bleeding. After discharge, she was treated with azathioprine 100 mg per day and colchicine 1.2 mg per day for 3 months, and no evidence of hemoptysis recurrence was encountered after pulmonary artery embolization, warfarin was administered for 3 months, and then changed to aspirin. At 6 months after discharge, the patient remained asymptomatic with no recurrence of the leg pain.
Discussion
Behcet's disease is a chronic, systemic, inflammatory disease. Its major manifestations are recurrent oral and genital aphthous ulcerations. Furthermore, Behcet's disease may involve neurologic, cardiovascular, pulmonary, and musculoskeletal systems, and cardiovascular manifestations have been described in 7∼49% of patients. Veins are frequently affected, and their involvements result in both superficial thrombophlebitis and deep venous thrombosis in 30∼40% of patients. Arterial complications occur in 1∼7% of patients and pulmonary artery involvement is observed in 1% (4-6).
Men are much more likely to be affected by arterial disease.
Pulmonary artery aneurysm has a poor prognosis and is one of the leading causes of death in Behcet's disease patients.
Hemoptysis, when massive and untreated, has a mortality rate of ＞50% (7). Medical treatments based on steroids and on immunosuppressive drugs, such as cyclophosphamide or azathioprine, have been tried, but although some have reported successful treatment results and aneurysmal regression for immunosuppressive treatments (8, 9) , embolization with medical therapy more widely accepted (10) . Surgical treatment may be considered for refractory vessel disease.
Venous thrombosis of the lower extremities and superior or inferior vena cava occlusion frequently occur in Behcet's disease patients. Unfractionated heparin and anticoagulation historically represent the mainstay treatment for deep vein thrombosis, but anticoagulation therapy cannot be used in patients with a high risk of hemorrhagic complications. Thus, anticoagulation therapy can be administered via flow-directed regional thrombolytic therapy, which is based on the direct regional infusion of concentrated thrombolytic agent from an ipsilateral peripheral vein into the deep venous system (11).
Because secondary pulmonary embolism due to small fragments can occur, IVC filtration must be performed before direct regional thrombolytic therapy.
Immunosuppressive agents are recommended for the management of acute deep vein thrombosis in Behcet's disease, but anticoagulation is not recommended by the EULAR guidelines (12) . The 'vasculo-Behcet' concept has been adopted when vascular complications dominate clinical features (13) .
There is some debate about use of non-soluble coil or soluble gelfoam. In this case, pulmonary artery aneurysm was treated successfully by coil embolization and deep vein thrombosis was treated by regional thrombolytics infusion. Because of coexistence bleeding risk and thrombotic complication, we must concern to determine treatment in vasculo-Behcet's disease.
The early detection of vascular lesions and appropriate treatment are essential for the optimal care of these patients.
